The United States Food and Drug Administration approved a hemodynamic patient monitoring system by Tensis Medical, a healthcare products manufacturer based in San Diego, California. The TL-300 non-invasive monitoring system is designed to provide physicians and healthcare providers with biometric data on a patient’s blood pressure and cardiovascular waveform. This level of monitoring isn’t possible with other non-invasive systems.

According to a press release by the company, the TL-300 gathers biometric and hemodynamic data from a specialized sensor, wrist frame and bracelet. Data from these monitoring devices is then transmitted to a monitor.

Dr. Oliver Goedje is the medical director of Tensys. In prepared remarks, he said, "The TL-300 represents our continued commitment to delivering next generation, non-invasive, hemodynamic monitoring tools." He continued, "This new system will not only enhance our current product offering, but will serve as a platform as we add cardiac output and additional hemodynamic parameters in the near future."

The TL-300 hemodynamic monitoring system is the latest entry in the company’s T-Line product family. Since T-Line products first entered the market, they have been used by over 50,000 patients.

Tensys Medical stated that it will provide more information about the device at OneMedForum, a medical trade show. OneMedForum will take place in 2013 in San Francisco, California.

References

www.tensysmedical.com/pdf/TensysFDA510_FinalJan2013.pdf